CorrectSequence Reports Long-Term Success of CS-206 Base Editing Therapy for Sickle Cell Disease
CorrectSequence Therapeutics announced 15-month follow-up results showing that its CS-206 base editing therapy maintained lasting efficacy and a favorable safety profile in a patient with sickle cell disease, with no vaso-occlusive crises or anemia observed.